Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
201.91
+0.28 (+0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Understanding Biogen's Position In Biotechnology Industry Compared To Competitors
December 27, 2023
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today
December 26, 2023
Via
Benzinga
Top 3 Healthcare Stock Picks for the New Year
December 25, 2023
Buy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals.
Via
InvestorPlace
Looking Into Biogen's Recent Short Interest
December 21, 2023
Via
Benzinga
5 Biotech stocks tapping into unmet mental health treatment needs
December 20, 2023
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.
Via
MarketBeat
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
December 13, 2023
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today
December 11, 2023
Via
Benzinga
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023
From
Biogen Inc.
Via
GlobeNewswire
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
The increased understanding and widespread acceptance of mental health concerns have put psychedelic stocks in the spotlight.
Via
InvestorPlace
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Sage Therapeutics, Inc.
Via
Business Wire
The Latest Analyst Ratings for Biogen
December 07, 2023
Via
Benzinga
Comparative Study: Biogen And Industry Competitors In Biotechnology Industry
November 28, 2023
Via
Benzinga
Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today
November 16, 2023
Via
Benzinga
Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry
November 14, 2023
Via
Benzinga
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout
December 12, 2023
While the market continues towards making new highs, it is falling short of making a breakout rally. Forthcoming CPI data and the upcoming FOMC meeting may be the catalyst for same.
Via
Talk Markets
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
December 09, 2023
These stocks aren't worth the risk.
Via
The Motley Fool
Expert Ratings for Biogen
November 09, 2023
Via
Benzinga
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
December 07, 2023
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects
December 07, 2023
Biogen Inc (NASDAQ: BIIB) has been in focus due to its treatment for early-stage Alzheimer’s disease.
Via
Benzinga
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
November 21, 2023
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Via
Benzinga
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
December 04, 2023
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.
Via
MarketBeat
Topics
Bonds
Exposures
Debt Markets
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
November 17, 2023
Biotech companies are edging closer to finding the answers behind Alzheimer's disease.
Via
Investor's Business Daily
Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review
November 10, 2023
The major indexes ended long win streaks. Datadog led earnings winners.
Via
Investor's Business Daily
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
The real competitive battle is about to begin, and it will last a long time.
Via
The Motley Fool
These Analysts Revise Their Forecasts On Biogen After Q3 Results
November 09, 2023
Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings.
Via
Benzinga
Thoughts For Thursday: Staying On Top - Barely
November 09, 2023
The stock market continues to be full of worry, but is managing to stay on top this week, so far. It is worth noting that yesterday's close brought levels back to those of a month ago.
Via
Talk Markets
Biogen (BIIB) Q3 2023 Earnings Call Transcript
November 08, 2023
BIIB earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.